Search the Newsreel

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares

David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, …

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates

LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 …

LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with …

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades

An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. …

How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record

Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook

LeMaitre Vascular reported a Q2 2026 earnings and revenue miss, leading to a significant after-hours stock drop. Despite strong year-over-year growth and margin expansion, the company cut its full-year organic revenue growth outlook due to foreign exchange pressures, Middle East shipping delays, and cardiac …

4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan

David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), sold 12,415 shares of company stock on August 3, 2026, at a weighted average price of $10.0461 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on January 9, 2026. …

Hercules Capital (HTGC) Could Be 13% Undervalued Following Earnings And Dividend News

Hercules Capital (HTGC) has garnered investor attention after reporting strong Q2 and H1 2026 results with higher revenue and net income. Despite a recent dip in its year-to-date share price, the stock is considered 13.2% undervalued by analysts, with a fair value target of …

LeMaitre says Artegraft is now approved in 56 countries

LeMaitre (NASDAQ: LMAT) reported strong Q2 2026 financial results with net sales up 10% year-over-year to $70.4 million and diluted EPS up 23% to $0.74. A key growth driver was Artegraft, whose sales increased by 34%, now representing 21% of total sales and approved …

Precision Trading with Oculis Holding Ag (OCS) Risk Zones

Oculis Holding Ag (OCS) shows divergent sentiment across different time horizons, suggesting choppy conditions with elevated downside risk. The article provides institutional trading strategies including long, momentum breakout, and short strategies, along with a multi-timeframe signal analysis detailing support and resistance levels. It emphasizes …

Moleculin Biotech (NasdaqCM:MBRX) Stock Forecast & Analyst Predictions

Moleculin Biotech (MBRX) is forecast to increase earnings by 54.7% and revenue by 74.8% annually, with EPS expected to grow by 75.4%. The company's lead drug candidate, Annamycin, is progressing through pivotal Phase 2/3 MIRACLE trials for relapsed or refractory acute myeloid leukemia (R/R …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 14.61% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT) is a significant player in the healthcare sector, specifically in medical instruments for vascular surgery, with a market capitalization of $2.37 billion. The company shows strong financial health with 11.20% revenue growth, a 16.55% return on equity, and a forward …

LeMaitre Vascular earnings on deck as margin gains test continues

LeMaitre Vascular is set to announce its second-quarter earnings, with investors closely watching its ability to maintain significant margin expansion and accelerate profit growth. Analysts anticipate earnings of $0.81 per share on revenue of $71.5 million, reflecting substantial year-over-year growth. The company's premium valuation …

LeMaitre Q2 2026 Financial Results

LeMaitre Vascular, Inc. reported strong Q2 2026 financial results with sales up 10% to $70.4 million and EPS up 23% to $0.74, driven by a 34% increase in Artegraft sales and operational efficiencies. The company announced a quarterly dividend of $0.25/share and provided optimistic …

LeMaitre: Q2 Earnings Snapshot

LeMaitre Vascular Inc. (LMAT) reported a second-quarter profit of $17.1 million, or 74 cents per share, on revenue of $70.4 million. The medical device maker anticipates revenue for the current quarter to be between $66.3 million and $68.3 million, with full-year earnings projected at …

Sei Investments Co. Has $6 Million Position in Federal Agricultural Mortgage Corporation $AGM

Sei Investments Co. has increased its stake in Federal Agricultural Mortgage Corporation (AGM) by 48.1% in the first quarter, now holding 40,469 shares valued at approximately $6 million. Institutional investors collectively own 68.03% of the company, which recently exceeded quarterly earnings expectations and pays …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results

AirSculpt Technologies (NASDAQ: AIRS) announced it will release its second quarter 2026 financial results before market open on Monday, August 10, 2026, followed by a conference call at 8:30 a.m. Eastern Time. The company will also participate in Canaccord Genuity's 46th Annual Growth Conference …

Cullen/Frost Bankers Is Maintained at Buy by TD Cowen

This article states that TD Cowen has maintained its "Buy" rating for Cullen/Frost Bankers. No additional details are provided regarding the reasoning or financial implications of this rating.

LeMaitre Vascular, Inc. $LMAT Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 34.9% in the first quarter, selling 27,990 shares and retaining 52,252 shares valued at approximately $5.7 million. The medical instruments supplier reported strong Q1 earnings, beating estimates with $0.68 EPS …

First Trust Advisors LP Increases Position in Federal Agricultural Mortgage Corporation $AGM

First Trust Advisors LP significantly increased its stake in Federal Agricultural Mortgage Corporation (NYSE:AGM) by 124% in the first quarter, now holding 35,662 shares valued at $5.29 million. Institutional investors collectively own 68.03% of the company, which recently exceeded earnings and revenue estimates and …

Earnings Preview: AIRS to Report Financial Results Pre-market on August 10

LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6%

LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6% Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street's revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter's revenue guidance of $67.3 million underwhelmed, coming in …

LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results

LeMaitre Vascular (LMAT) Earnings Date and Reports 2026

Wide Open Agriculture’s Lupin Fibre Clears Key CSIRO Tests, Targets Booming Functional Fibre Market

Does Federal Agricultural Mortgage's (AGM) EPS Surge Reflect Deeper, Sustainable Efficiency Gains?

Dekon Food and Agriculture Group Completes US$100 Million Convertible Bond Issue

Ocular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash

Ocular Therapeutix announced its second-quarter 2026 results, reporting $13.5 million in product revenue, a net loss of $78.8 million, and a strong cash position of $598.6 million. The company is advancing AXPAXLI for wet AMD, with an NDA submission planned for Q4 2026, supported …

Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights

Ocular Therapeutix reported flat second-quarter 2026 revenue of $13.5 million compared to the previous year, alongside an increased net loss of $78.8 million. The company is advancing its investigational drug Axpaxli for wet AMD, with plans to submit an NDA in Q4 2026, and …

Ocular Therapeutix (OCUL) Stock Faces Axpaxli Hopes Against Deepening Losses

Ocular Therapeutix (OCUL) saw a modest 3% stock increase after Q2 2026 earnings, which showed flat revenue and widened net losses, keeping the focus on long-term growth and its pipeline. The company's bullish case hinges on Axpaxli, its wet AMD therapy, showing strong clinical …

4D Molecular Therapeutics (FDMT) to Announce Earnings on Monday

4D Molecular Therapeutics (FDMT) is set to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts expecting a loss of $1.04 per share and revenue of $3.62 million. The company's shares have recently declined by 3.3%, and the stock …

AirSculpt Technologies Announces Second Quarter 2026 Earnings Release and Conference Call, Plans Presentation at Canaccord Genuity Growth Conference

AirSculpt Technologies (NASDAQ: AIRS) announced it will release its second quarter 2026 financial results on Tuesday, August 13, 2026, before the market opens. The company will also host a conference call and webcast on the same day at 8:00 AM ET to discuss these …

Moleculin Biotech completes $9.3M equity financing

CULLEN/FROST BANKERS INC : TD COWEN RAISES TARGET PRICE TO $185 FROM $169

TD Cowen has increased its target price for Cullen/Frost Bankers Inc. (CFR.N) from $169 to $185. This information was reported by Reuters. The article emphasizes that the content reflects only the author's opinion and should not be used as the sole basis for investment …

Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements

Moleculin Biotech successfully completed a public offering, raising approximately $9.3 million gross. The company entered into a Placement Agency Agreement with Roth Capital Partners and a Securities Purchase Agreement with investors. Additionally, directors and officers have agreed to 60-day lock-up periods following the closing, …